TABLE 3.
Clinical characteristics of patients with urinary tract infections treated with faropenema
| Parameter | Result |
|---|---|
| No. of patients | 63 |
| Median age in yrs (IQR) | 72 (23) |
| No. (%) male | 24 (38) |
| No. (%) of underlying diseases of the urinary systemb | 23 (37) |
| No. (%) of subjects needing post-urological surgery | 14 (22) |
| No. (%) of causative pathogens | |
| Escherichia coli | 54 (86) |
| Klebsiella pneumoniae | 9 (14) |
| Median inhibition zone diam (minimum–maximum, IQR) in mm | 20.0 (16.0–26.0, 3.0) |
| eMIC (minimum–maximum) in mg/Lc | 1.0 (1.3–2.2) |
| No. (%) of subjects with complicated UTI | 56 (89) |
| Diagnosis, no. (%) of subjects with | |
| Acute pyelonephritis | 32 (51) |
| Prostatitis | 6 (10) |
| Unclassifiable | 8 (13) |
| Bacteremia | 10 (16) |
| Cystitis | 17 (27) |
| No. (%) of subjects who switched from other antimicrobial agents | |
| As empirical treatment | 31 (49) |
| CMZ | 11 (17) |
| MEPM | 15 (24) |
| PIPC/TAZ | 3 (5) |
| Fluoroquinolone | 2 (3) |
| FOM | 1 (2) |
| No. (%) of subjects on therapy regimen with FRPM | |
| Monotherapy | 36 (57) |
| Combination therapy with FOM | 25 (40) |
| Combination therapy with a fluoroquinolone | 2 (3) |
| Duration of antimicrobial treatment | |
| Total median duration of treatment in days (IQR) | 16.0 (18) |
| Median duration of FRPM treatment in days (IQR) | 14.0 (17) |
| Clinical effectiveness, no. (%) of subjects | |
| 28-day relapse/28-day reinfection after completion of FRPM | 10 (16)/3 (5) |
| 90-day relapse/90-day reinfection after completion of FRPM | 16 (25)/4 (6) |
| All-cause mortality/ICU admission | 0/0 |
a
CMZ, cefmetazole; eMIC, estimated MIC; FOM, fosfomycin; IQR, interquartile range; MEPM, meropenem; PIPC/TAZ, piperacillin-tazobactam; ICU, intensive care unit.
b
Including after urological surgery.
c
The eMIC in the minimum range is more than the median eMIC due to the approximate function calculated by 9 to 24 (mm).